Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin
US2010159474A1
Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
CN102203607A
Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system
CN102257386A
Prognosis and risk assessment in stroke patients by determining the level of marker peptides
EP2180322A1
Prognostic biomarkers for the progression of primary chronic kidney disease
CN110346577A
Application of the Procalcitonin (PCT) in the risk stratification and prognosis of patient for suffering from primary uninfection
EP2148203A1
Azurophilic granule proteases as markers in cardiological diseases
CN101896816A
Method for detecting analytes
EP2131200A1
A marker for graft failure and mortality
EP2108958A1
Pro-Endothelin-1 for the prediction of impaired peak oxygen consumption
EP2107377A1
Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
EP2101178A1
Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes
DE102008007218A1
Preventive treatment of patients with mild cognitive disorders, which based on increase of circulation-relevant peptide-biomarker measurable in circulation, with medicament comprising e.g. angiotensin converting enzyme-inhibitor
DE102007037068A1
Detecting analytes of biological samples, comprises providing reversible binding partner, adding biological sample and binding analyte to reversibly immobilized analyte binder, adding stripping buffer, detecting analyte in stripping buffer
EP2020603A1
Method for risk stratification in stable coronary artery disease
DE102007029766A1
Detecting an analyte in a biological sample comprises using a complex of the type A-B-C-D, where A is a solid phase, B and C are components of a reversible binding pair and D is an analyte binder
DE102007021443A1
Diagnosis and risk stratification using NT-proET-1
DE102007022367A1
Method for the determination of amino-terminal pro-ANP in overweight patients
DE102007010834A1
Method for in-vitro diagnosis or risk classification or outcome prognosis of heart failure for New york heart association patient, involves utilizing determination of marker proatrial natriuretic peptide
